Drug Trial Radar · NCT04170153
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Dec 20, 2019
Primary completion
Oct 14, 2026
Study completion Oct 14, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Nov 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.
Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M1774Drug
M1774 will be administered orally throughout the study.
NiraparibDrug
Niraparib will be administered orally throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1, A4 and A5: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: Day 1 to Day 21 of Cycle 1 (Each Cycle is of 21 days)
- Part A1, A3, A4, A5 and B1: Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs) and Death According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0Time frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
- Part A1, A3, A4, A5 and B1: Number of Participants With Grade 3 or Higher Laboratory Findings According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0Time frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
- Part A1, A3, A4, A5 and B1: Number of Participants With Abnormalities in Vital SignsTime frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
- Part A1, A3, A4, A5 and B1: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram (ECG) FindingsTime frame: Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years
- Part A2: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose (AUC 0-24h) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
- Part A2: Area Under the Plasma Concentration Curve From Time Zero to Infinity Post Dose (AUC 0-inf) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
- Part A2: Maximum Observed Plasma Concentration (Cmax) of Tuvusertib (M1774)Time frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
- Part A2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve (Frel[AUC]) of Tuvusertib (M1774) Under Fed Condition as Compared to Fasting ConditionTime frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
- Part A2: Relative Bioavailability Based on Maximum Observed Plasma Concentration (Frel[Cmax]) of Tuvusertib (M1774) Under Fed Condition as Compared to Fasting ConditionTime frame: Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)
- Part A3: Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to 2.2 years
- Part B1: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: Day 1 to Day 28 of Cycle 1 (Each Cycle is of 28 days)
- Part A1, A4, A5 and B1: To Determine the Recommended Dose Expansion (RDE) for Tuvusertib (M1774) monotherapy globally, in Japanese and in Chinese participants With Metastatic or Locally Advanced Unresectable Solid Tumors and in combination with NiraparibTime frame: Assessed up to approximately 2.2 years
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
NEXT Oncology
Austin, Texas
Mary Crowley Cancer Research Centers
Dallas, Texas
The Methodist Hospital Research Institute
Houston, Texas
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
Houston, Texas
Beijing Cancer Hospital
Beijing, China
National Cancer Center Hospital - Dept of Experimental Therapeutics
Chūōku, Japan
National Cancer Center Hospital East - Dept of Experimental Therapeutics
Kashiwa-shi, Japan
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona, Spain
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, Spain
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
Valencia, Spain
Addenbrooke's Hospital - Dept of Oncology
Cambridge, United Kingdom
The Christie Hospital - Dept of Oncology
Manchester, United Kingdom
Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, United Kingdom
Royal Marsden Hospital - Dept of Oncology
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.